Abstract

A REVIEW ON VARIOUS ANALYTICAL METHODS FOR ESTIMATION OF SILODOSIN AND TADALAFIL

Ayushi Shah*, Sapna Rathod and Maulik Mehta

ABSTRACT

Tadalafil and silodosin are effective treatment options in men with BPH (Benign prostatic hyperplasia) who have LUTS (lower urinary tract symptoms), but the combination of both is more effective and feasible in treating LUTS of BPH. According to the 2020 guidelines of the European Association of Urology, both α1 adrenoceptor blockers (α1-blockers) and phosphodiesterase type 5 inhibitors (PDE5-Is) are recommended as the first-line medical treatment for lower urinary tract symptoms (LUTS) associated with BPH Silodosin is in a class of medications called alpha-blockers. It relieves the symptoms of BPH by relaxing the muscles of the bladder and prostate. It has a strong uroselective and acts as a 1- adrenoreceptor antagonist (selectivity for the prostate). Tadalafil belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The mechanisms of PDE5-I responsible for improvements in LUTS include the inhibition of PDE5 isoenzymes present in the bladder, prostate, urethra, and supporting vasculature, and consequent increases in the intracellular nitric oxide–cyclic guanosine monophosphate concentration, relaxation of the muscle cells in these structures, improved blood perfusion, and reduced afferent signaling from the urogenital tract. Silodosin (8 mg) and Tadalafil IP (5 mg) are recommended in recently approved FDC for the effective treatment options in man with BPH who have LUTS. The aim of this review is to focus on update of determination of Silodosin and Tadalafil in pharmaceutical preparation used in RP-HPLC, UV- Spectroscopic method. 

Keywords: Silodosin, Tadalafil, UV, RP HPLC, HPTLC, LCMS, Stability method.